CNC-01 / JW Pharma - LARVOL DELTA

C&C New Drug Research Institute, Acute Myeloid Leukemia Treatment Preclinical Results Released at AACR [Google translation] (BioTimes) - "C&C New Drug Research Institute announced on the 29th that it had presented the nonclinical study results of CNC-01 (tentative code name), a STAT5/STAT3 dual inhibitor candidate currently under development as a treatment for acute myeloid leukemia (AML), at the 2025 American Association for Cancer Research (AACR 2025) held in Chicago, USA....In addition, CNC-01 monotherapy showed a strong tumor suppression effect in an AML animal model that did not respond to BCL-2 inhibitors, which are currently used as standard AML treatments, and the therapeutic effect was further enhanced when administered in combination with BCL-2 inhibitors. In particular, tumor responses corresponding to complete remission (CR) and partial remission (PR) were observed in both monotherapy and combination trials."

Preclinical • Acute Myelogenous Leukemia